| Patent application number | Description | Published |
|---|
| 20080275121 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
| 20080275122 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 11-06-2008 |
| 20080275123 | N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to a method for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a phase transfer agent. This specification also describes a formulation having antimicrobial activity comprising a N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
| 20080275126 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 11-06-2008 |
| 20080287395 | Phospholipid Compositions for Contact Lens Care and Preservation of Pharmaceutical Compositions - The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long hydrocarbon chain. Such molecular arrangements are what make the phospholipids of formula (I) highly water soluble, e.g., the length of the hydrocarbon chain assists to maintain solubility and efficacy of the molecules for the uses described herein. The synthetic phospholipids described herein have been found to be particularly useful as antimicrobial preservatives for ophthalmic, otic and nasal pharmaceutical compositions, especially ophthalmic compositions. These compounds may also be utilized to disinfect contact lenses. The invention is based in-part upon a finding that the antimicrobial activity of the synthetic phospholipids is affected by the ionic strength of the compositions in which the compounds are contained. The provision of compounds having limited ionic strengths is therefore preferred. | 11-20-2008 |
| 20090197838 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 08-06-2009 |
| 20090298956 | SELF-PRESERVED EMULSIONS - The use of multifunctional synthetic compounds to both stabilize and preserve therapeutic emulsions is described. The multifunctional synthetic compounds have unique molecular arrangement wherein a phosphate group is linked to one, two or three quaternary ammonium functionalities via a substituted propenyl group, and each quaternary ammonium functionality is further linked to at least one hydrocarbon chain. The pharmaceutical emulsions which include these multifunctional compounds may be prepared without heating or homogenization, and may not require the use of any additional stabilizing or preserving agents. | 12-03-2009 |
| 20100021561 | SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS - The use of borate/amino alcohol/zinc systems to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being “self-preserved”. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions. | 01-28-2010 |
| 20100021562 | SELF PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS - The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being ‘self-preserved’. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions. | 01-28-2010 |
| 20100056537 | PHARMACEUTICAL COMPOSITION HAVING RELATIVELY LOW IONIC STRENGTH - The present invention is directed to the provision of pharmaceutical compositions such as multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy preservative efficacy requirements in the United States and/or Europe. The compositions include sorbate or a non-polymeric diquaternary ammonium compound for enhancing preservation efficacy. Further, the compositions typically have relatively low ionic strengths to assist in maintaining such efficacy. | 03-04-2010 |
| 20100076045 | STABILIZED PHARMACEUTICAL SUB-MICRON SUSPENSIONS AND METHODS OF FORMING SAME - The present invention is directed to a pharmaceutical submicron suspension and a method of forming the submicron suspension. The submicron suspension is useful for delivery of relatively hydrophobic and/or low solubility therapeutic agent. The submicron suspension and method of forming the submicron suspension typically employ a polymeric material that aids in preventing aggregation of the therapeutic agent. | 03-25-2010 |
| 20100160342 | Compositions of Topical Ocular Solutions to Deliver Effective Concentrations of Active Agent to the Posterior Segment of the Eye - The present invention relates to development of efficacious pharmaceutical compositions comprising an active agent, such as the free base or hydrochloride salt of tandospirone, for topical delivery to the eye for the treatment of retinal disorders. | 06-24-2010 |
| 20100204181 | N-HALOGENATED AMINO ACID FORMULATIONS COMPRISING PHOSPHINE OR AMINE OXIDES - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and a phosphine oxide or amine oxide. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding a phosphine oxide or amine oxide to said formulation. | 08-12-2010 |
| 20100210730 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 08-19-2010 |
| 20100266664 | Devices And Methods For Ophthalmic Drug Delivery - Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an eye of the subject with an ophthalmic drug delivery device comprising a body having a proximal end and a distal end, wherein the body comprises a styrene elastomer matrix and a drug in contact with the matrix, wherein release of the drug from the device occurs over time following contacting of the device with the eye of the subject. | 10-21-2010 |
| 20110003803 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC, OTIC, OR NASAL INFECTIONS - The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections. | 01-06-2011 |
| 20110060044 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 03-10-2011 |
| 20110071091 | INJECTABLE AQUEOUS OPHTHALMIC COMPOSITION AND METHOD OF USE THEREFOR - The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent. | 03-24-2011 |
| 20110071116 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 03-24-2011 |
| 20110082145 | OLOPATADINE COMPOSITIONS AND USES THEREOF - The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: | 04-07-2011 |
| 20110124734 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 05-26-2011 |
| 20110135743 | CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 06-09-2011 |
